Sector
PharmaceuticalsOpen
₹81.07Prev. Close
₹81.83Turnover(Lac.)
₹3.51Day's High
₹81.67Day's Low
₹78.252 Week's High
₹129.0752 Week's Low
₹61Book Value
₹-63.95Face Value
₹10Mkt Cap (₹ Cr.)
169.06P/E
0EPS
0Divi. Yield
030 Aug 2024
12:00 AM
AGM
Announcement Date: 30 Aug, 2024
5 Sep 2023
12:00 AM
BookCloser
15 Jan 2025
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 21.56 | 21.56 | 21.56 | 23.79 |
Preference Capital | 130 | 130 | 130 | 30 |
Reserves | -140.78 | -121.02 | -96.65 | -66.52 |
Net Worth | 10.78 | 30.54 | 54.91 | -12.73 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 53.7 | 33.41 | 33.77 | 3.25 |
yoy growth (%) | 60.72 | -1.08 | 937.63 | 152.43 |
Raw materials | -25.94 | -15.85 | -12.7 | -0.92 |
As % of sales | 48.31 | 47.46 | 37.61 | 28.35 |
Employee costs | -15.82 | -15.08 | -11.48 | -5.62 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -28.35 | -28.87 | -16.61 | -15.64 |
Depreciation | -5.12 | -4.67 | -4.14 | -4.23 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 7.39 | -3.08 | -6.51 | 0.9 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 60.72 | -1.08 | 937.63 | 152.43 |
Op profit growth | -5.65 | 148.34 | -6.22 | -35.49 |
EBIT growth | -3.76 | 100.46 | -5.86 | -23.33 |
Net profit growth | -1.77 | 61.97 | 11.06 | -1.66 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,787.4 | 137.43 | 4,32,960 | 1,181.05 | 0.75 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,012.5 | 79.59 | 1,65,003.32 | 594 | 0.48 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,525.9 | 26.92 | 1,25,285.64 | 1,438.15 | 0.84 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,238.9 | 61.67 | 1,12,502.67 | 485 | 0.84 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,557.5 | 55.53 | 1,07,385.94 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Independent Director
G V L Prasad
Chairman (Non-Executive)
R T Ravi
Non Executive Director
Avinash Ravi
Independent Director
Tangirala Malati
Independent Director
Satish Khivsara
Independent Director
Raj Kamal Prasad Verma
Managing Director & CEO
Jitendra Shah
Company Sec. & Compli. Officer
Keyur Doshi
Additional Director
Popatlal M Kathariya
Additional Director
Dipti Shah
Additional Director
SATYA CHIGURUPATI
Additional Director
Sumanth Karlapudi
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Krebs Biochemicals & Industries Ltd
Summary
Krebs Biochemicals & Industries Ltd (Formerly Krebs Biochemicals Ltd), promoted by R T Ravi in 1991 is engaged in the manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same.Krebs develops commercially viable biotech processes for application in medicine, agriculture and industry. Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies.KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA. KBL went to public with an IPO in 1994. During 2001-02, the company launched Vitamin C(I P Grade) through Fermentation Process. The Company commissioned 2.5 MW Co-generation Power Plant at Unit II in Vizag during 2003-04 and started operations on it from July, 2004 onwards.
Read More
What is the Krebs Biochemicals & Industries Ltd share price today?
The Krebs Biochemicals & Industries Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹78.41 today.
What is the Market Cap of Krebs Biochemicals & Industries Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Krebs Biochemicals & Industries Ltd is ₹169.06 Cr. as of 25 Apr ‘25
What is the PE and PB ratio of Krebs Biochemicals & Industries Ltd?
The PE and PB ratios of Krebs Biochemicals & Industries Ltd is 0 and -1.35 as of 25 Apr ‘25
What is the 52 Week High and Low of Krebs Biochemicals & Industries Ltd?
The 52-week high/low is the highest and lowest price at which a Krebs Biochemicals & Industries Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Krebs Biochemicals & Industries Ltd is ₹61 and ₹129.07 as of 25 Apr ‘25
What is the CAGR of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd's CAGR for 5 Years at 2.11%, 3 Years at -20.51%, 1 Year at 13.34%, 6 Month at 5.79%, 3 Month at -19.36% and 1 Month at 9.69%.
What is the shareholding pattern of Krebs Biochemicals & Industries Ltd?
The shareholding pattern of Krebs Biochemicals & Industries Ltd is as follows:
Promoters - 72.74 %
Institutions - 0.50 %
Public - 26.76 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
